

UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC)

Data and Safety Monitoring Plan (DSMP) Templates for Protocols



**Table of Contents**

# [DSMP for Phase 1 Dose Escalation Trial (Single Site)](#_DSMP_for_Phase) 3

# [DSMP for Phase I Non-Dose Finding Phase I Trial (Single Site)](#_bookmark1) 7

# [DSMP for Phase 2, 3, or 4 Trial (Single Site)](#_bookmark2) 10

# [DSMP for Phase 2 or Pilot Study with a Study Lead-in Phase](#_bookmark3) 13

# [DSMP for a Non-Therapeutic Study (Single Site)](#_bookmark4) 17

# [DSMP for a Non- Therapeutic Study (Minimal Risk – Single Site)](#_bookmark5) 21

# [DSMP for a Non-Therapeutic Study (Multicenter)](#_bookmark6) 23

# [DSMP for a Phase 1 Dose Escalation Trial (Multicenter)](#_bookmark7) 26

# [DSMP for a Phase I Non-Dose Finding Trial (Multicenter)](#_bookmark8) 31

# [DSMP for a Phase 2, 3, or 4 Trial (Multicenter)](#_bookmark9) 35

# DSMP for a Phase 2, 3, or 4 Trial with a Safety Lead-in (Multicenter) 39

# [Risk Assessment for Institutional Trials for DSMC Reviews](#_bookmark11) 43

**Appendix N.1 (Single Site) Phase I Dose Escalation**

**Data and Safety Monitoring Plan for a Phase I Dose Escalation Institutional Trial**

**Oversight and Monitoring Plan**

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and participant safety for all HDFCCC institutional clinical trials. A summary of DSMC activities for this trial includes:

* Participant monitoring prior to requested dose escalations
* Review of participant data in each dosing cohort
* Review of serious adverse events
* Approval of dose escalation by DSMC Chair (or Vice Chair)
* Minimum of biennial regulatory auditing

**Monitoring and Reporting Guidelines**

Investigators will conduct a continuous review of data and participant safety at weekly site committee meetings. The discussions are documented in the site committee meeting minutes.

All institutional therapeutic dose escalation Phase I trials are generally designated with a high-risk assessment; therefore, the source documents for all enrolled participants in each dosing cohort are monitored by a DSMC DSA prior to approval of the dosing cohort. This includes a review of all study information through the first post-Dose Limiting Toxicity period (DLT period) visit of the trial up until the maximum tolerated dose (MTD) is determined or for the first cycle of treatment for Rolling Six cohorts. Once the MTD is determined and the cohort expansion phase has started, the DSMC DSA will audit 20 percent of the participants enrolled in this cohort through the first three cycles of treatment for each participant reviewed until study is closed to accrual.

The DSA will send both a Monitoring Visit Report (MVR) and an Action Item Report (AIR) to the study team within 1 calendar month after the monitoring visit is complete for the study team to resolve all action items from the Action Item Report (AIR) report within 8 weeks. The due date for the completion of the action items may be extended for up to an additional 2 months for extenuating circumstances, if approved by the DSMC. The AIR report must be completed by the study team prior to the next monitoring review of this study. Additionally, the action items from the AIR Report must be deemed answered and complete by the DSA after the report has been submitted by the study team; hence, the completed AIR must be sent to the DSMC by 4 weeks prior to the deadline for the DSA’s review and confirmation of these completed action items. If the study team is granted a second extension by the DSMC Director, then the DSA will have 4 weeks after the report has been provided to the DSMC to review and confirm the responses on the AIR.

A limited regulatory review (i.e., reviewing protocol and consent versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by the DSMC for regulatory compliance.

Scheduled auditing of participant source documents is complete after all files have been reviewed for three cycles of treatment for 20% of the enrolled participants in this cohort, with no more than 10 total participants reviewed during the course of auditing the expansion cohort. However, regulatory reviews of the trial, safety reviews (i.e., Serious Adverse Event (SAE) reviews and Protocol Violation (PV) reviews), as well as audit/inspection preparation (as applicable) will continue until study closure.

1. **Review and Oversight Requirements**
   1. **Adverse Event Monitoring**

All clinically significant adverse events (AEs), whether or not considered expected or unexpected, and whether or not considered associated with the investigational agent(s) or study procedure, will be entered into OnCore, UCSF’s Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to investigational agent(s) or study procedure. Attribution categories are:

* + - **Definite** – clearly related to the investigational agent(s) or study procedure.
    - **Probable** – likely related to the investigational agent(s) or study procedure.
    - **Possible** – may be related to the investigational agent(s) or study procedure.
    - **Unrelated** – clearly not related to the investigational agent(s) or study procedure.

All clinically significant adverse events entered into OnCore will be reviewed on a weekly basis at the site committee meetings. The site committee will review and discuss the selected toxicity, the toxicity grade, and attribution assignment.

* 1. **Serious Adverse Event Reporting**

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

* + - Death,
    - Life-threatening adverse experience\*,
    - Inpatient hospitalization or prolongation of existing hospitalization,
    - Persistent or significant disability/incapacity,
    - Congenital anomaly/birth defect, or cancer, or
    - Any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above,
    - Event that changes the risk/benefit ratio of the study.

\* A life-threatening adverse experience is any AE that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event reporting will be in accordance with all IRB regulations. For trials conducted under an investigational new drug (IND) application, the SAE will be reported in accordance with Code of Federal Regulation Title 21 Part 312.32 and will be reported on a MedWatch form.

UCSF IRB website for guidance in reporting serious adverse events: <https://irb.ucsf.edu/adverse-event>

MedWatch forms and information:

[www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm)

All serious adverse events are entered into OnCore. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at the DSMC meetings, which take place every eight weeks. The date the SAE report was sent to all required reporting agencies will be documented in OnCore.

If a death occurs during the treatment phase of the study, or within 30 days after the last administration of the study drug(s) or research-related procedure, and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Principal Investigator or his/her designee must notify the DSMC Chair (or Vice Chair) and DSMC Director within one business day.

* 1. **Dose Escalations**

At the time of dose escalation, the PI submits a written and signed Dose Escalation/Expansion Report to the DSMC Chair (or Vice Chair) and DSMC Director describing the cohorts, dose levels, adverse events, safety reports, and any Dose Limiting Toxicities (DLTs) observed, in accordance with the protocol. The report will be reviewed by the DSMC Chair or Vice Chair and written authorization to proceed or a request for more information will be issued within two business days of the request. The report is then reviewed at the subsequent DSMC Committee meeting. In the event that the committee does not concur with the DSMC Chair’s (or Vice Chair’s) decision, study accrual is held while further investigation takes place. Also, if there are AIRs that are past the due date for completions (i.e., post 8 week timeline or post 12-16 week timeline if extensions were granted), then the Dose Escalation/Expansion review will be postponed until these action items are all addressed by the study team.

* 1. **Review of Adverse Event Rates**

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the PI will notify the DSMC via report at the time the increased rate is identified . The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the PI voluntarily holds enrollment in the trial due to safety issues, the DSMC Chair (or Vice Chair) and DSMC Director must be notified within one business day via e-mail, and the IRB must be notified as per IRB reporting regulations.

**Data and Safety Monitoring Committee Contacts:**

|  |
| --- |
| Katie Kelley, MD (DSMC Chair) |
| 415-353-9888  [Katie.kelley@ucsf.edu](mailto:Katie.kelley@ucsf.edu) Box 3211  UCSF HDFCCC  San Francisco, CA 94158 |
| John McAdams (DSMC Director) 415-476-8496  [John.mcadams@ucsf.edu](mailto:John.mcadams@ucsf.edu) Box 0981  UCSF HDFCCC  San Francisco, CA 94158 |

**Appendix N.2 (Single Site) High-Risk Non-Dose Finding Phase I Trial**

**Data and Safety Monitoring Plan for a High-Risk Non-Dose Finding Phase I Institutional Trial (Single Site)**

1. **Oversight and Monitoring Plan**

The UCSF Helen Diller Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and participant safety for all HDFCCC institutional clinical trials. A summary of DSMC activities for this trial includes:

* + Participant monitoring on a quarterly basis (depending on study accrual)
  + Review of serious adverse events
  + Minimum of biennial regulatory auditing

1. **Monitoring and Reporting Guidelines**

Investigators will conduct a continuous review of data and participant safety at weekly site committee meetings where the results of each participant’s treatment are discussed and documented in the site committee minutes.

All institutional non-dose finding therapeutic trials, are generally designated with a high-risk assessment. The data is monitored by an assigned Data and Safety Auditor (DSA) on a quarterly basis throughout the year (depending on accrual) as participants are enrolled in the trial. Each participant chart is reviewed through the first month of study drug therapy. The DSA will send both a Monitoring Visit Report (MVR) and an Action Item Report (AIR) to the study team within 1 calendar month after the monitoring visit is complete for the study team to resolve all action items from the Action Item Report (AIR) report within 8 weeks. The due date for the completion of the action items may be extended for up to an additional 2 months for extenuating circumstances, if approved by the DSMC. The AIR report must be completed by the study team prior to the next review of this study. Additionally, the action items from the AIR Report must be deemed answered and complete by the DSA after the report has been submitted by the study team; hence, the completed AIR must be sent to the DSMC by 4 weeks prior to the deadline for the DSA’s review and confirmation of these completed action items. If the study team is granted a second extension by the DSMC Director, then the DSA will have 4 weeks after the report has been provided to the DSMC to review and confirm the responses on the AIR.

A limited regulatory review (i.e., reviewing protocol and consent versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by the DSMC for regulatory compliance.

Once monitoring of all enrolled participants in these trials has been completed, regulatory reviews, safety reviews (i.e., Serious Adverse Event (SAE) and Protocol Violation (PV) report reviews), and audit/inspection preparation (as applicable) will continue until study closure.

1. **Review and Oversight Requirements**
2. **Adverse Event Monitoring**

All clinically significant adverse events (AEs), whether or not considered expected or

unexpected and whether or not considered associated with the investigational agent(s) or study procedure, will be entered into OnCore, UCSF’s Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an

assignment of attribution or relationship to investigational agent(s) or study procedure. Attribution categories are:

* **Definite** – clearly related to the investigational agent(s) or study procedure.
* **Probable** – likely related to the investigational agent(s) or study procedure.
* **Possible** – may be related to the investigational agent(s) or study procedure.
* **Unrelated** – clearly not related to the investigational agent(s) or study procedure.

All adverse events entered into OnCore® will be reviewed on a weekly basis at the site committee meetings. The site committee will review and discuss the selected toxicity, the toxicity grade, and attribution assignment.

1. **Serious Adverse Event Reporting**

By definition, an Adverse Event is defined as a serious adverse event (SAE) according to the following criteria:

* Death,
* Life-threatening adverse experience\*,
* Inpatient hospitalization or prolongation of existing hospitalization,
* Persistent or significant disability/incapacity,
* Congenital anomaly/birth defect, or cancer, or
* Any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above,
* Event that changes the risk/benefit ratio of the study.

\* A life-threatening adverse experience is any AE that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event reporting will be in accordance with all IRB regulations. For trials conducted under an investigational new drug (IND) application, the SAE will be reported in accordance with Code of Federal Regulation Title 21 Part 312.32 and will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events: <https://irb.ucsf.edu/adverse-event>

Med Watch forms and information: [www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm)

All serious adverse events are entered into OnCore. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at the DSMC meetings, which

take place every eight weeks. The date the SAE report was sent to all required reporting agencies will be documented in OnCore.

If a death occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s) and is determined to be possibly, probably, or

definitely related either to the investigational drug or any research related procedure, the Investigator or his/her designee must notify the DSMC Chair (or Vice Chair) and DSMC Director within one business day.

1. **Review of Adverse Event Rates**

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Principal Investigator will notify the DSMC via report at the time the increased rate is identified. The report will indicate if the incident of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the Investigator stops enrollment or stops the study due to safety issues, the DSMC Chair (or Vice Chair) and the DSMC Director must be notified within one business day via e-mail and the IRB must be notified as per their reporting regulations.

**Data and Safety Monitoring Committee Contacts:**

|  |
| --- |
| Katie Kelley, MD (DSMC Chair) |
| 415-353-9888  [Katie.kelley@ucsf.edu](mailto:Katie.kelley@ucsf.edu) Box 3211  UCSF HDFCCC  San Francisco, CA 94158 |
| John McAdams (DSMC Director) 415-476-8496  [John.mcadams@ucsf.edu](mailto:John.mcadams@ucsf.edu) Box 0981  UCSF HDFCCC  San Francisco, CA 94158 |

**Appendix N.3 (Single Site) Phase II, III, or IV Institutional Trial**

**Data and Safety Monitoring Plan for a Phase II, III, and IV Institutional Trial**

1. **Oversight and Monitoring Plan**

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for auditing data quality and participant safety for all HDFCCC institutional clinical trials. A summary of DSMC activities for this trial includes:

* Annual auditing (depending on trial accrual)
* Review of serious adverse events
* Minimum of biennial regulatory auditing

1. **Monitoring and Reporting Guidelines**

Investigators will conduct a continuous review of data and participant safety at monthly site committee meetings where the results of each participant’s treatment are discussed and documented in the site committee minutes.

The DSMC DSA will audit up to a maximum of three cycles of treatment for each participant selected for the annual audit. Approximately twenty percent of the participants enrolled in the study will be reviewed until the study is closed to accrual. For example, if there are 10 participants enrolled in the trial, then only 2 participants will be required to be reviewed by the DSA.

For ‘greater than minimal risk’ single-site Phase 2 or 3 institutional non-therapeutic trials, the assigned DSMC DSA will audit approximately 20% of enrolled participants per year (up to a maximum of 3 per year), with a maximum of 10 participant charts audited overall from the start of the study until the study is closed to accrual. For example, if there are 10 participants enrolled in the trial in a given year, two participants (20%) will be reviewed that year. A limited regulatory review will occur at each auditing visit (i.e., review of the approved protocol and ICF versions, along with the Delegation of Authority (DOA) Log, Financial Disclosure Form (FDF), and the FDA 1572 form); however, a complete regulatory review will occur on a biennial basis by the DSMC for regulatory compliance.

The DSA will send both a Monitoring Visit Report (MVR) and an Action Item Report (AIR) to the study team within 1 calendar month after the monitoring visit is complete for the study team to resolve all action items from the Action Item Report (AIR) report within 8 weeks. The due date for the completion of the action items may be extended for up to an additional 2 months for extenuating circumstances, if approved by the DSMC. The AIR report must be completed by the study team prior to the next monitoring review of this study. Additionally, the action items from the AIR Report must be deemed answered and complete by the DSA after the report has been submitted by the study team; hence, the completed AIR must be sent to the DSMC by 4 weeks prior to the deadline for the DSA’s review and confirmation of these completed action items. If the study team is granted a second extension by the DSMC Director, then the DSA will have 4 weeks after the report has been provided to the DSMC to review and confirm the responses on the AIR.

A limited regulatory review (i.e., reviewing protocol and consent versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by the DSMC for regulatory compliance. An abbreviated regulatory review (i.e., reviewing protocol and consent

versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by the DSMC for regulatory compliance.

Auditing of all enrolled participants in these trials will be complete after 20% of enrolled participants have been audited through three cycles of treatment (or a total of 10 participants have been reviewed). However, regulatory reviews of the trial, safety reviews (i.e., Serious Adverse Event (SAE) reviews and Protocol Violation (PV) reviews), and audit/inspection preparation (as applicable) will continue until trial closure.

1. **Review and Oversight Requirements**
   1. **Adverse Event Monitoring**

All Grade 3-5 adverse events (AEs), whether or not considered to be expected or unexpected and whether or not considered to be associated with the use of the

investigational agent(s) or study procedure, will be entered into OnCore®, UCSF’s Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to investigational agent or study procedure. Attribution categories are:

* + - **Definite** – clearly related to the investigational agent(s) or study procedure.
    - **Probable** – likely related to the investigational agent(s) or study procedure.
    - **Possible** – may be related to the investigational agent(s) or study procedure.
    - **Unrelated** –clearly not related to the investigational agent(s) or study procedure.

All Grade 3-5 adverse events entered into OnCore will be reviewed on a monthly basis at the Site Committee meetings. The Site Committee will review and discuss the selected toxicity, the toxicity grade, and attribution assignment.

* 1. **Serious Adverse Event Reporting**

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

* + - Death,
    - Life-threatening adverse experience\*,
    - Inpatient hospitalization or prolongation of existing hospitalization,
    - Persistent or significant disability/incapacity,
    - Congenital anomaly/birth defect, or cancer, or
    - Any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above,
    - Event that changes the risk/benefit ratio of the study.

\* A life-threatening adverse experience is any AE that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event reporting will be in accordance with all IRB regulations. For trials conducted under an investigational new drug (IND) application, the SAE will be reported in accordance with Code of Federal Regulation Title 21 Part 312.32 and will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events: <https://irb.ucsf.edu/adverse-event>

Med Watch forms and information: [www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm)

All serious adverse events are entered into OnCore. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every six weeks. The date the SAE is sent to all required reporting agencies will be documented in OnCore.

If the SAE involves a subject death, and is determined to be possibly, probably or definitely related to the investigational drug or any research related procedure, the event must be reported to the DSMC Chair (or Vice Chair) and DSMC Director within one business day.

* 1. **Review of Adverse Event Rates**

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Principal Investigator will notify the DSMC via report at the time the increased rate is identified. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the Investigator voluntarily holds enrollment or stops the study due to safety issues, the DSMC Chair (or Vice Chair) and the DSMC Director must be notified within one business day and the IRB must be notified as per IRB reporting regulations.

**Data and Safety Monitoring Committee Contacts:**

|  |
| --- |
| Katie Kelley, MD (DSMC Chair) |
| 415-353-9888  [Katie.kelley@ucsf.edu](mailto:Katie.kelley@ucsf.edu) Box 3211  UCSF HDFCCC  San Francisco, CA 94158 |
| John McAdams (DSMC Director) 415-476-8496  [John.mcadams@ucsf.edu](mailto:John.mcadams@ucsf.edu) Box 0981  UCSF HDFCCC  San Francisco, CA 94158 |

**Appendix N.4 (Single Site) Phase II Trial or Pilot Study with Safety Lead-In Phase**

**Data and Safety Monitoring Plan: Institutional (Single Site) Phase II Trial or Pilot Study with Safety Lead-In Phase**

1. **Oversight and Monitoring Plan**

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for auditing data quality and participant safety for all HDFCCC institutional clinical trials. A summary of DSMC activities for this trial includes:

* Review of all participant data in safety lead-in phase
* Approval to enroll past the safety lead-in phase by DSMC Chair or Vice Chair
* Annual auditing after completion of the safety lead-in phase
* Review of serious adverse events
* Minimum of biennial regulatory auditing

1. **Monitoring and Reporting Guidelines**

Investigators will conduct a continuous review of data and participant safety at monthly site committee meetings where the results of each participant’s treatment are discussed and documented in the site committee minutes.

All institutional Phase II or Pilot trials with a safety lead-in are designated with a high-risk assessment during the safety lead-in phase and a moderate risk assessment for the remainder of the trial. During the safety lead-in phase, the DSMC will audit all visits through the first cycle of treatment for all participants enrolled in this phase of the trial. However, if there are AIRs that are past the due date for completions (i.e., post 8 week timeline or post 12-16 week timeline if extensions were granted), then the safety lead-in review will be postponed until these action items are all addressed by the study team.

After the completion of enrollment in the safety lead-in phase, the Principal Investigator will submit a report to the DSMC Chair (or Vice Chair) outlining all AEs, SAEs, and DLTs (as defined in the protocol) with a request to proceed onto the next phase of the study. For the Safety Lead-in Cohorts, the HDFCCC PI and study team representative must notify the DSMC once the final participant in the cohort is enrolled in the trial and will be required to complete the [DSMC Study Safety Lead-In Report](https://ucsf.app.box.com/folder/164371240161?s=dtk2zc1qm3w3s3rwqooerwqdmmvell3t) and [DSMC Dose](https://ucsf.app.box.com/folder/164371240161?s=dtk2zc1qm3w3s3rwqooerwqdmmvell3t) [Escalation/Expansion and Safety Lead-In Request](https://ucsf.app.box.com/folder/164371240161?s=dtk2zc1qm3w3s3rwqooerwqdmmvell3t) [Checklist.](https://ucsf.app.box.com/folder/164371240161?s=dtk2zc1qm3w3s3rwqooerwqdmmvell3t) The DSMC Director will review and provide approval on a case by case basis for Dose Escalation review that requires a more

expedited review timeline (i.e., less than 4 weeks’ notice). The study team representative must complete the report and checklist and send to the DSMC DSA to review prior to PI's sign off. The DSMC DSA will then review the report for completeness and accuracy, and will submit the completed DSMC Study Safety Lead-In Report, signed and dated by the PI, to the DSMC Chair (or Vice Chair) and Director requesting approval from the DSMC prior to further enrollment in the trial as per protocol. The DSMC Chair (or Vice Chair) will grant approval of this request within 2 business days from receipt from the DSMC DSA if there aren’t any significant safety issues (i.e., SAEs, protocol violations, etc.) in the participant cohort that was audited*.*

Within two business days of receipt, the DSMC Chair or designee will review the report and issue written authorization to proceed or a request for more information. The report is then reviewed at the subsequent DSMC meeting.

After DSMC authorization to enroll beyond the safety lead-in phase is granted, study data is audited annually, with a random selection of participants reviewed. The DSA will send both a Monitoring Visit Report (MVR) and an Action Item Report (AIR) to the study team within 1 calendar month after the monitoring visit is complete for the study team to resolve all action items from the Action Item Report (AIR) report within 8 weeks. The due date for the completion of the action items may be extended up to an additional 2 months for extenuating circumstances if approved by the DSMC. The AIR report must be completed by the study team prior to the next monitoring review of this study. Additionally, the action items from the AIR Report must be deemed answered and complete by the DSA after the report has been submitted by the study team; hence, the completed AIR must be sent to the DSMC by 4 weeks prior to the deadline for the DSA’s review and confirmation of these completed action items. If the study team is granted a second extension by the DSMC Director, then the DSA will have 4 weeks after the report has been provided to the DSMC to review and confirm the responses on the AIR.

A limited regulatory review (i.e., reviewing protocol and consent versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by the DSMC for regulatory compliance.

Auditing of all enrolled participants in these trials will be complete after 20% of enrolled participants (or 10 total participants) have been audited through three cycles of treatment.

However, regulatory reviews of the trial, safety reviews (i.e., Serious Adverse Event (SAE) reviews and Protocol Violation (PV) reviews), and audit/inspection preparation (as applicable) will continue until study closure.

1. **Review and Oversight Requirements**
   1. **Adverse Event Monitoring**

All Grade 3-5 adverse events (AEs), whether or not considered to be expected or unexpected and whether or not considered to be associated with the investigational agent(s) or study procedure, will be entered into OnCore, UCSF’s Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to the investigational agent(s) or study procedure. Attribution categories are:

* + - **Definite** – clearly related to the investigational agent(s) or study procedure.
    - **Probable** – likely related to the investigational agent(s) or study procedure.
    - **Possible** – may be related to the investigational agent(s) or study procedure.
    - **Unrelated** – clearly not related to the investigational agent(s) or study procedure.

All Grade 3-5 adverse events entered into OnCore will be reviewed on a monthly basis at the UCSF Coordinating Center’s Site Committee. The Site Committee will review and discuss the selected toxicity, the toxicity grade, and the attribution assignment.

* 1. **Serious Adverse Event Reporting**

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

* + - Death,
    - Life-threatening adverse experience\*,
    - Inpatient hospitalization or prolongation of existing hospitalization,
    - Persistent or significant disability/incapacity,
    - Congenital anomaly/birth defect, or cancer, or
    - Any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above,
    - Event that changes the risk/benefit ratio of the study.

\* A life-threatening adverse experience is any AE that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event reporting will be in accordance with all IRB regulations. For trials conducted under an investigational new drug (IND) application, the SAE will be reported in accordance with Code of Federal Regulation Title 21 Part 312.32 and will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events: <https://irb.ucsf.edu/adverse-event>

Med Watch forms and information: [www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm)

All serious adverse events are entered into OnCore, All SAEs are reviewed and monitored by the DSMC on an ongoing basis and discussed at DSMC meetings, which take place every eight weeks. The date the SAE report was sent to all required reporting agencies will be documented in OnCore.

If an SAE involves death and occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s), and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, then the event must be reported to the DSMC Chair (or Vice Chair) and DSMC Director within one business day.

* 1. **Review of Adverse Event Rates**

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Principal Investigator is responsible for notifying the DSMC via report at the time the increased rate is identified. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator’s Brochure or package insert.

If at any time the Principal Investigator stops enrollment or stops the study due to safety issues, the DSMC Chair (or Vice Chair) and DSMC Director must be notified within one business day.

**Data and Safety Monitoring Committee Contacts:**

|  |
| --- |
| Katie Kelley, MD (DSMC Chair) |
| 415-353-9888  [Katie.kelley@ucsf.edu](mailto:Katie.kelley@ucsf.edu) Box 3211  UCSF HDFCCC  San Francisco, CA 94158  John McAdams (DSMC Director) 415-476-8496  [John.mcadams@ucsf.edu](mailto:John.mcadams@ucsf.edu) Box 0981  UCSF HDFCCC  San Francisco, CA 94158 |

**Appendix N.5 (Single Site) Non-therapeutic Institutional Study**

**Data and Safety Monitoring Plan for a Non-therapeutic Institutional Study for a Non-Therapeutic Greater than Minimal Risk, Low Risk Category Study**

1. **Oversight and Monitoring Plan**

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and participant safety for all HDFCCC institutional clinical trials. This non-therapeutic study of a new diagnostic agent has been determined to be “greater than minimal risk.” and low risk. A summary of DSMC activities for this trial includes:

* Annual auditing
* Review of serious adverse events
* Minimum of biennial regulatory auditing

The UCSF HDFCCC Data and Safety Monitoring Committee (DSMC) is responsible for participant safety for all HDFCCC institutional clinical trials. Greater than minimal risk non-therapeutic studies are characterized as low risk studies due to a research component which introduces risk without therapeutic intent (e.g., a study including an invasive procedure such as a biopsy for research purposes), as there isn’t administration of drugs or complementary therapy that puts the participants at significant risk.

1. **Monitoring and Reporting Guidelines**

Investigators will conduct a continuous review of data and participant safety at monthly site committee meetings where the status of each participant is discussed and documented in the site committee minutes.

For “greater than minimal risk” non-therapeutic studies, the assigned Data and Safety Auditor (DSA) will audit up to three participants once per year. A total of 20% of the enrolled participants in the study will be reviewed, with a maximum of ten participant charts reviewed until study closure.

If blood or tissue banking studies are determined to be “greater than minimal risk”, then only Serious Adverse Events (SAEs) recorded in OnCore will be reviewed at each DSMC meeting.

After completion of each auditing visit, the DSA will send both a Monitoring Visit Report (MVR) and an Action Item Report (AIR) to the study team within 1 calendar month after the monitoring visit is complete for the study team to resolve all action items from the Action Item Report (AIR) report within 8 weeks. The due date for the completion of the action items may be extended for up to an additional 2 months for extenuating circumstances, if approved by the DSMC. The AIR report must be completed by the study team prior to the next auditing review of this study.

Additionally, the action items from the AIR Report must be deemed answered and complete by the DSA after the report has been submitted by the study team; hence, the completed AIR must be sent to the DSMC by 4 weeks prior to the deadline for the DSA’s review and confirmation of these completed action items. If the study team is granted a second extension by the DSMC Director, then the DSA will have 4 weeks after the report has been provided to the DSMC to review and confirm the responses on the AIR.

AA limited regulatory review (i.e., reviewing protocol and consent versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by the DSMC for regulatory compliance.

Auditing of all enrolled participants in these studies will be complete after 10 enrolled participants have been audited. However, regulatory reviews of the study, safety reviews

(i.e., Serious Adverse Event (SAE) reviews and Protocol Violation (PV) reviews), and audit/inspection preparation (as applicable) will continue until the study is closed by the IRB.

1. **Review and Oversight Requirements**
   1. **Adverse Event Monitoring**

All Grade 3-5 adverse events (AEs) related to study procedures, whether considered expected or unexpected, will be entered into OnCore, UCSF’s Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to study intervention or procedure. Attribution categories are:

* + - **Definite** – clearly related to the study intervention or procedure.
    - **Probable** – likely related to study intervention or procedure.
    - **Possible** – may be related to study intervention or procedure.
    - **Unrelated** – clearly not related to the study intervention or procedure.

All clinically significant adverse events entered into OnCore® will be reviewed on a monthly basis at the Site Committee meetings.

* 1. **Serious Adverse Event Reporting**

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

* + - Death,
    - Life-threatening adverse experience\*,
    - Inpatient hospitalization or prolongation of existing hospitalization,
    - Persistent or significant disability/incapacity,
    - Congenital anomaly/birth defect, or cancer, or
    - Any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above,
    - Event that changes the risk/benefit ratio of the study.

\* A life-threatening adverse experience is any AE that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event reporting will be in accordance with all IRB regulations. For studies conducted under an investigational new drug (IND) application, the SAE will be reported in accordance with Code of Federal Regulation Title 21 Part 312.32 and will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events: <https://irb.ucsf.edu/adverse-event>

Med Watch forms and information:

[www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm)

All serious adverse events are entered into OnCore. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every eight weeks. The date the SAE report was sent to all required reporting agencies will be documented in OnCore.

If a death occurs during the treatment phase of the study and is determined to be possibly, probably, or definitely related either to the study intervention or procedure, the Investigator or his/her designee must notify the DSMC Chair or Vice Chair and DSMC Director within one business day.

* 1. **Review of Adverse Event Rates**

If at any time the Investigator voluntarily holds enrollment or stops the study due to safety issues, the DSMC Chair (or Vice Chair) and the DSMC Director must be notified within one business day and the IRB must be notified as per IRB reporting requirements.

**Data and Safety Monitoring Committee Contacts:**

|  |
| --- |
| Katie Kelley, MD (DSMC Chair) |
| 415-353-9888  [Katie.kelley@ucsf.edu](mailto:Katie.kelley@ucsf.edu) Box 3211  UCSF HDFCCC  San Francisco, CA 94158 |
| John McAdams (DSMC Director) 415-476-8496  [John.mcadams@ucsf.edu](mailto:John.mcadams@ucsf.edu) Box 0128  UCSF HDFCCC  San Francisco, CA 94158 |

**Appendix N.6 (Single or Multicenter Site): Non-therapeutic Institutional Study – Minimal Risk**

**Data and Safety Monitoring Plan for a Minimal Risk Institutional Study**

1. **Oversight and Monitoring Plan**

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and participant safety for all HDFCCC institutional clinical trials. This non-therapeutic study has been determined to be “minimal risk.” A summary of DSMC activities for this trial includes:

* + Review of serious adverse events and protocol violations only.

The UCSF HDFCCC Data and Safety Monitoring Committee (DSMC) is responsible

for participant safety for all HDFCCC institutional clinical trials. Minimal risk non-therapeutic studies are characterized as studies without risk due to a research component which introduces procedures which don’t involve risk to the participants (e.g., a blood draw study).

Safety reviews (i.e., Serious Adverse Event (SAE) reviews and Protocol Violation (PV) reviews) will continue until the study is closed by the IRB. Regulatory reviews will not be performed for minimal risk institutional studies and are only performed for above minimal risk studies.

1. **Serious Adverse Event Reporting**

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

* + Death,
  + Life-threatening adverse experience\*,
  + Inpatient hospitalization or prolongation of existing hospitalization,
  + Persistent or significant disability/incapacity,
  + Congenital anomaly/birth defect, or cancer, or
  + Any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above,
  + Event that changes the risk/benefit ratio of the study.

\* A life-threatening adverse experience is any AE that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event reporting will be in accordance with all IRB regulations. UCSF IRB website for guidance in reporting serious adverse events: <https://irb.ucsf.edu/adverse-event>

Med Watch forms and information:

[www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm)

All serious adverse events are entered into OnCore, as well as submitted to the IRB. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every eight weeks. The date the SAE report was sent to all required reporting agencies will be documented in OnCore.

If a death occurs during the course of study participation and is determined to be possibly, probably, or definitely related either to the study procedure, the Investigator or his/her designee must notify the DSMC Chair or Vice Chair and DSMC Director within one business day.

1. **Review of Adverse Event Rates**

If at any time the Investigator voluntarily holds enrollment or stops the study due to safety issues, the DSMC Chair (or Vice Chair) and the DSMC Director must be notified within one business day and the IRB must be notified as per IRB reporting requirements.

**Data and Safety Monitoring Committee Contacts:**

|  |
| --- |
| Katie Kelley, MD (DSMC Chair) |
| 415-353-9888  [Katie.kelley@ucsf.edu](mailto:Katie.kelley@ucsf.edu) Box 3211  UCSF HDFCCC  San Francisco, CA 94158  John McAdams (DSMC Director) 415-476-8496  [John.mcadams@ucsf.edu](mailto:John.mcadams@ucsf.edu) Box 0128  UCSF HDFCCC  San Francisco, CA 94158 |

**Appendix N.7 (Multicenter) Non-Therapeutic Multicenter Institutional Study**

**Data and Safety Monitoring Plan for a Non-therapeutic Institutional Study for a Non- Therapeutic Greater than Minimal Risk, Low Risk Category Study**

**Data and Safety Monitoring Plan for a Non-Therapeutic Multicenter Institutional Study**

1. **Oversight and Monitoring Plan**

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and participant safety for all HDFCCC institutional clinical trials. This non-therapeutic study of a new diagnostic agent has been determined to be “greater than minimal risk.” and low risk. A summary of DSMC activities for this study includes:

* + Annual auditing of participant data
  + Review of serious adverse events
  + Minimum of annual DSMB reports
  + Minimum of biennial regulatory auditing

The UCSF HDFCCC Data and Safety Monitoring Committee (DSMC) is responsible for participant safety for all domestic sites for HDFCCC Multicenter and Consortium institutional clinical studies. The International sites must be audited by a Clinical Research Organization (CRO) that is formally approved by the HDFCCC Cancer Center Clinical Research Oncology Committee (CCCROC) and the HDFCCC DSMC via the [HDFCCC](https://cancer.ucsf.edu/itr/sm_files/Policy_on_Minimum_Standards_for_Partnerships_with_International_CROs_current.pdf) [Policy of Minimum Standards for Partnership with International CROs.](https://cancer.ucsf.edu/itr/sm_files/Policy_on_Minimum_Standards_for_Partnerships_with_International_CROs_current.pdf)

For “greater than minimal risk” non-therapeutic studies, the assigned Data and Safety Auditor (DSA) will audit up to three of the enrolled participants once per year with a total of 20% of the total number of participants enrolled in the study at UCSF and at least 1 participant at each participating site. A total of 1 participant per site will be required to be reviewed, unless there are participants enrolled in cohorts that require all participants to be reviewed (i.e., study lead-in or rolling 6 cohorts).

If blood or tissue banking studies are determined to be “greater than minimal risk”, then only Serious Adverse Events (SAEs) recorded in OnCore will be reviewed at each DSMC meeting for these studies.

The DSA will send both a Monitoring Visit Report (MVR) and an Action Item Report (AIR) to the study team within 1with one calendar month after the monitoring visit is complete for the study team to resolve all action items from the Action Item Report (AIR) report within 8 weeks. The due date for the completion of the action items may be extended for up to an additional 2 months for extenuating circumstances, if approved by the DSMC. The AIR report must be completed by the study team prior to the next monitoring review of this study.

Additionally, the action items from the AIR Report must be deemed answered and complete by the DSA after the report has been submitted by the study team; hence, the completed AIR must be sent to the DSMC by 4 weeks prior to the deadline for the DSA’s review and confirmation of these completed action items. If the study team is granted a second extension by the DSMC Director, then the DSA will have 4 weeks after the report has been provided to the DSMC to review and confirm the responses on the AIR.

Auditing in these studies will be complete after 20% of the total number of participants enrolled in the trial at UCSF and at least 1 participant at each participating site(s) has been reviewed.

Page **23** Revision #7 (27.MAR.2025)

A total of 1 participant per site will be required to be reviewed, unless there are participants enrolled in cohorts

that require all participants to be reviewed (i.e., study lead-in or rolling 6 cohorts).

However, regulatory reviews of the study, safety reviews (i.e., Serious Adverse Event (SAE) reviews and Protocol Violation (PV) reviews), and audit/inspection preparation (as applicable) will continue until the study is closed by the IRB. An abbreviated regulatory review (i.e., reviewing protocol and consent versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by the DSMC for regulatory compliance.

The Principal Investigator at the UCSF Coordinating Center will hold the role of Study Chair. The Study Chair is responsible for the overall conduct of the study and for monitoring its safety and progress at all participating sites. Investigators will conduct a continuous review of data and participant safety at monthly site committee meetings where the status of each participant is discussed and documented in the site committee minutes.

1. **Multicenter communication**

The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical study. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites. The following issues will be discussed as appropriate:

* + Enrollment information.
  + Adverse events (i.e., new adverse events and updates on unresolved adverse events and new safety information).
  + Protocol Violations.
  + Other issues affecting the conduct of the study.

Adverse events reporting to the DSMC will include reports from both the UCSF Coordinating Center, as well as the participating sites. The DSMC will be responsible for monitoring all data entered in OnCore at the UCSF Coordinating Center and the participating sites as per the study-specific guidelines. The data (i.e., copies of source documents) from the participating sites will be downloaded into the CRA console of OnCore prior to the monitoring visits in order for the DSMC to perform a remote audit of the participating site’s compliance with the protocol.

1. **Review and Oversight Requirements**
   1. **Adverse Event Monitoring**

All Grade 3-5 adverse events (AEs) related to study procedures, whether considered expected or unexpected, will be entered into OnCore, UCSF’s Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to the study intervention or procedure.

Attribution categories are:

* + - **Definite**– clearly related to the study intervention or procedure.
    - **Probable** –likely related to the study intervention or procedure.
    - **Possible** – may be related to the study intervention or procedure.
    - **Unrelated** – clearly not related to the study intervention or procedure.

All Grade 3-5 adverse events entered into OnCore will be reviewed on a monthly basis at the UCSF Site Committee meetings. All adverse events entered into OnCore will be reviewed on a monthly basis at the UCSF Coordinating Center Site Committee meetings. All clinically significant adverse events must be reported to the UCSF Coordinating Center by the participating sites within 10 business days of becoming aware of the event or during the next scheduled monthly conference call, whichever is sooner. The UCSF Site Committee will review and discuss the selected toxicity, the toxicity grade, and the attribution assignment for adverse events that occurred at the UCSF Coordinating Center and the participating sites.

* 1. **Serious Adverse Event Reporting**

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

* + - Death,
    - Life-threatening adverse experience\*,
    - Inpatient hospitalization or prolongation of existing hospitalization,
    - Persistent or significant disability/incapacity,
    - Congenital anomaly/birth defect, or cancer, or
    - Any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above,
    - Event that changes the risk/benefit ratio of the study.

\* A life-threatening adverse experience is any AE that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event reporting will be in accordance with all IRB regulations. For studies conducted under an investigational new drug (IND) application, the SAE will be reported in accordance with Code of Federal Regulation Title 21 Part 312.32 and will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events: <https://irb.ucsf.edu/adverse-event>

Med Watch forms and information:

[www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm)

All serious adverse events are entered into OnCore. All SAEs, whether expected or unexpected, must be reported to the UCSF Coordinating Center within one business day of becoming aware of the event.

The SAEs are reviewed and monitored by the UCSF Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every eight weeks. The date of the submission of the SAE report to all required reporting agencies will be documented in OnCore.

If a death occurs during the treatment phase of the study and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Study Chair at the UCSF Coordinating Center or the assigned

designee must be notified within one business day from the participating site(s) and the Study Chair must then notify the DSMC Chair (or Vice Chair) and the DSMC Director within one business day of this notification.

* 1. **Review of Adverse Event Rates**

If at any time the Study Chair voluntarily holds enrollment or stops the study due to safety issues, the DSMC Chair (or Vice Chair) and DSMC Director must be notified within one business day and the IRB must be notified as per their reporting requirements.

* 1. **Data and Safety Monitoring Board (DSMB) Reports**

Data and Safety Monitoring Board (DSMB) Reports which provide information on trial accrual, participant safety, and data integrity will be provided to all sites, including the domestic and international sites, on an annual basis. The DSMB Report will be signed by the DSMC Chair (or Vice Chair) and provided to the DSMC Committee for formal review at the next scheduled DSMC Committee meeting.

**Data and Safety Monitoring Committee Contacts:**

|  |
| --- |
| Katie Kelley, MD (DSMC Chair) |
| 415-353-9888  [Katie.kelley@ucsf.edu](mailto:Katie.kelley@ucsf.edu) Box 3211  UCSF HDFCCC  San Francisco, CA 94158 |
| John McAdams (DSMC Director) 415-476-8496  [John.mcadams@ucsf.edu](mailto:John.mcadams@ucsf.edu) Box 0981  UCSF HDFCCC  San Francisco, CA 94158 |

**Appendix N.8 (Multicenter) Phase 1 Dose Escalation**

**Data and Safety Monitoring Plan for a Multicenter Institutional Trial (Phase 1 Dose Escalation)**

1. **Oversight and Monitoring Plan**

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and participant safety for all HDFCCC institutional clinical trials and cancer-specific trials at UCSF. A summary of DSMC activities for this trial includes:

* Participant monitoring prior to dose escalation.
* Review of participant data in each cohort
* Approval of dose escalation by DSMC Chair or Vice Chair
* Review of serious adverse events
* Minimum of biennial regulatory auditing

1. **Monitoring and Reporting Guidelines**

The Principal Investigator at the UCSF Coordinating Center will hold the role of Study Chair. The Study Chair is responsible for the overall conduct of the trial and for monitoring its safety and progress at all participating sites. The Study Chair will conduct continuous review of data and participant safety at weekly UCSF Site Committee meetings. The discussions are documented in the UCSF Site Committee meeting minutes.

The UCSF HDFCCC Data and Safety Monitoring Committee (DSMC) is responsible for participant safety for all domestic sites for HDFCCC Multicenter and Consortium institutional clinical trials. The International sites must be monitored by a Clinical Research Organization (CRO) that is formally approved by the HDFCCC Cancer Center Clinical Research Oncology Committee (CCCROC) and the HDFCCC DSMC via the [HDFCCC Policy of Minimum Standards for Partnership with International CROs.](https://cancer.ucsf.edu/itr/sm_files/Policy_on_Minimum_Standards_for_Partnerships_with_International_CROs_current.pdf)

All institutional multicenter therapeutic dose escalation Phase I trials are generally designated with a high-risk assessment; therefore, the source documents for all enrolled participants in each dosing cohort are monitored by a DSMC DSA prior to approval of the dosing cohort. This includes a review of all study information through the first post-Dose Limiting Toxicity period (DLT period) visit of the trial up until the maximum tolerated dose (MTD) is determined or for the first cycle of treatment for Rolling Sic cohorts. Once the MTD is determined and the cohort expansion phase has started, the DSMC DSA will audit up to a maximum of three cycles of treatment for each participant reviewed. The assigned DSA will review approximately 20% of the total number of participants enrolled in the trial at UCSF and at least 1 participant reviewed at each participating site in the dose expansion phase of the study. .

The DSA will send both a Monitoring Visit Report (MVR) and an Action Item Report (AIR) to the study team within 1 calendar month after the monitoring visit is complete for the study team to resolve all action items from the Action Item Report (AIR) report within 8 weeks. The due date for the completion of the action items may be extended for up to an additional 2 months for extenuating circumstances, if approved by the DSMC. The

AIR report must be completed by the study team prior to the next monitoring review of this study.

Additionally, the action items from the AIR Report must be deemed answered and complete by the DSA after the report has been submitted by the study team; hence, the completed AIR must be sent to the DSMC by 4 weeks prior to the deadline for the DSA’s review and confirmation of these completed action items. If the study team is granted a second extension by the DSMC Director, then the DSA will have 4 weeks after the report has been provided to the DSMC to review and confirm the responses on the AIR.

A limited regulatory review (i.e., reviewing protocol and consent versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by the DSMC for regulatory compliance.

Monitoring of enrolled participants in the dose expansion portion of the trial will be complete after 20% of enrolled participants at UCSF and 1 participant from each participating site have been monitored through one cycle of treatment. However, regulatory reviews of the trial, safety reviews (i.e., Serious Adverse Event (SAE) reviews and Protocol Violation (PV) reviews), as well as audit/inspection preparation (as applicable) will continue until study closure.

**Multicenter communication**

The UCSF Coordinating Center includes the UCSF PI (Study Chair) and the UCSF study team. The UCSF Coordinating Center and provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites. The following issues will be discussed as appropriate:

* Enrollment information.
* Cohort updates (i.e., DLTs).
* Adverse events (i.e., new adverse events and updates on unresolved adverse events and new safety information).
* Protocol violations.
* Other issues affecting the conduct of the study.

**Dose Level Considerations**

The PI/Study Chair, participating investigators, and research coordinators from each site will review enrollment for each dose level cohort during the regularly scheduled conference calls. The dose level for ongoing enrollment will be confirmed for each participant scheduled to be enrolled at a site. Dose level assignments for any participant scheduled to begin treatment must be confirmed by the UCSF Coordinating Center via e-mail.

If a participant experiences a Dose Limiting Toxicity (DLT), the UCSF Coordinating Center will notify all sites within one business day of awareness. If the DLT occurs at a participating site, the local investigator must report the DLT to the UCSF Coordinating Center within one business day. The Study Chair has one business day (after first becoming aware of the event at either the UCSF Coordinating Center or the participating site) in which to report the DLT information to all participating sites.

Adverse events reporting to the DSMC will include reports from both the UCSF Coordinating Center, as well as the participating sites. The DSMC will be responsible for monitoring all data entered in OnCore at the UCSF Coordinating Center and the participating sites as per the study-specific guidelines. The data (i.e., redacted copies of

source documents) from the participating sites will be downloaded into the PC console of OnCore prior to the monitoring visits in order for the DSMC to perform remote monitoring of the participating site’s compliance with the protocol and applicable FDA regulations.

**Dose Escalations**

At the time of dose escalation, a written and signed Dose Escalation/Expansion Report will be submitted to the DSMC Chair (or Vice Chair) and DSMC Director describing the cohorts, dose levels, adverse events, safety reports, and any Dose Limiting Toxicities (DLTs) observed, in accordance with the protocol. The report will be reviewed by the DSMC Chair or Vice Chair and written authorization to proceed or a request for more information will be issued within two business days of the request. The report is then reviewed at the subsequent DSMC Committee meeting. In the event that the committee does not concur with the DSMC Chair’s (or Vice Chair’s) decision, study accrual is held while further investigation takes place. However, if there are AIRs that are past the due date for completions (i.e., post 8 week timeline or post 12-16 week timeline if extensions were granted), then the Dose Escalation/Expansion review will be postponed until these action items are all addressed by the study team.

1. **Review and Oversight Requirements**
   1. **Adverse Event Monitoring**

All clinically significant adverse events (AEs), whether or not considered to be expected or unexpected and whether or not considered to be associated with the use of study drug, will be entered into OnCore, UCSF’s Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to investigational agent or study procedure. Attribution categories are:

* + - **Definite** – clearly related to the investigational agent(s) or study procedure.
    - **Probable** – likely related to the investigational agent(s) or study procedure.
    - **Possible** – may be related to the investigational agent(s) or study procedure.
    - **Unrelated** – clearly not related to the investigational agent(s) or study procedure.

All adverse events entered into OnCore will be reviewed on a weekly basis at the UCSF Coordinating Center’s Site Committee meetings. The UCSF Site Committee will review and discuss the selected toxicity, grade, and the attribution assignment for the adverse events that occurred at both the UCSF Coordinating Center and the participating sites.

* 1. **Serious Adverse Event Reporting**

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

* + - Death,
    - Life-threatening adverse experience\*,
    - Inpatient hospitalization or prolongation of existing hospitalization,
    - Persistent or significant disability/incapacity,
    - Congenital anomaly/birth defect, or cancer, or
    - Any other experience that suggests a significant hazard, contraindication, side

effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above,

* + - Event that changes the risk/benefit ratio of the study.

\* A life-threatening adverse experience is any AE that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event reporting will be in accordance with all IRB regulations. For trials conducted under an investigational new drug (IND) application, the SAE will be reported in accordance with Code of Federal Regulation Title 21 Part 312.32 and will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events: <https://irb.ucsf.edu/adverse-event>

Med Watch forms and information:

[www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm)

All serious adverse events are entered into OnCore. All SAEs, whether expected or unexpected, must be reported to the UCSF Coordinating Center within 10 business days of becoming aware of the event or during the next scheduled conference all, whichever is sooner. The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every eight weeks. The date the SAE report was sent to all required reporting agencies will be documented in OnCore.

If a death occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s) and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Study Chair at the UCSF Coordinating Center or the assigned designee must be notified within 1 business day from the participating site(s) and the Study Chair must then notify the DSMC Chair (or Vice Chair) and the DSMC Director within one business day of this notification.

* 1. **Review of Adverse Event Rates**

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Study Chair at the UCSF Coordinating Center is responsible for notifying the DSMC at the time the increased rate is identified via a report. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator’s Brochure or package insert.

If at any time the Study Chair voluntarily holds enrollment or stops the study due to safety issues, the DSMC Chair (or Vice Chair) and the DSMC Director must be notified within one business day via e-mail and the IRB must be notified their reporting requirements.

* 1. **Data and Safety Monitoring Board (DSMB) Reports**

Data and Safety Monitoring Board (DSMB) Reports which provide information on trial accrual, participant safety, and data integrity will be provided to all sites, including the domestic and international sites, on an annual basis. The DSMB Report will be signed

by the DSMC Chair (or Vice Chair) and provided to the DSMC Committee for formal review at the next scheduled DSMC Committee meeting.

**Data and Safety Monitoring Committee Contacts:**

|  |
| --- |
| Katie Kelley, MD (DSMC Chair) |
| 415-353-9888  [Katie.kelley@ucsf.edu](mailto:Katie.kelley@ucsf.edu) Box 3211  UCSF HDFCCC  San Francisco, CA 94158 |
| John McAdams (DSMC Director) 415-476-8496  [John.mcadams@ucsf.edu](mailto:John.mcadams@ucsf.edu) Box 0981  UCSF HDFCCC  San Francisco, CA 94158 |

**Appendix N.9 (Multicenter) Non-Dose Finding Phase I Multicenter Trial**

**Data Safety Monitoring Plan for Non-Dose Finding Phase I Multicenter Trial**

1. **Oversight and Monitoring Plan**

The UCSF-Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data quality and participant safety for all HDFCCC institutional clinical trials. A summary of DSMC activities for this trial includes:

* Participant monitoring on a quarterly basis (depending on trial accrual)
* Review of serious adverse events
* Minimum of biennial regulatory auditing

1. **Monitoring and Reporting Guidelines**

The Principal Investigator at the UCSF Coordinating Center will hold the role of Study Chair. The Study Chair is responsible for the overall conduct of the trial and for monitoring its safety and progress at all participating sites. The Study Chair will conduct a review of data and participant safety at the weekly UCSF Site Committee meetings. The discussions are documented in the UCSF Site Committee meeting minutes.

The UCSF HDFCCC Data and Safety Monitoring Committee (DSMC) is responsible for participant safety for all domestic sites for HDFCCC Multicenter and Consortium institutional clinical trials. The International sites must be monitored by a Clinical Research Organization (CRO) that is formally approved by the HDFCCC Cancer Center Clinical Research Oncology Committee (CCCROC) and the HDFCCC DSMC via the [HDFCCC Policy of Minimum Standards for Partnership with International CROs.](https://cancer.ucsf.edu/itr/sm_files/Policy_on_Minimum_Standards_for_Partnerships_with_International_CROs_current.pdf)

All non-dose finding high risk Phase I therapeutic trials, regardless of the study phase, are generally designated with a high-risk assessment. The data is monitored by a Data and Safety Auditor (DSA) on a quarterly basis throughout the year as participants are enrolled in the trial. Each participant chart is reviewed through the first month of study drug therapy.

The DSA will send both a Monitoring Visit Report (MVR) and an Action Item Report (AIR) to the study team within 20 business days after the monitoring visit is complete for the study team to resolve all action items from the Action Item Report (AIR) report within 8 weeks. The due date for the completion of the action items may be extended for up to an additional 2 months for extenuating circumstances, if approved by the DSMC. The AIR report must be completed by the study team prior to the next monitoring review of this study. This due date for the completion of the action items may be extended an additional 2 months for extenuating circumstances approved by the DSMC. The AIR report must be completed by the study team prior to the next review of this study.

Additionally, the action items from the AIR Report must be deemed answered and complete by the DSA after the report has been submitted by the study team; hence, the completed AIR must be sent to the DSMC by 4 weeks prior to the deadline for the DSA’s review and confirmation of these completed action items. If the study team is granted a second extension by the DSMC Director, then the DSA will have 4 weeks after the report has been provided to the DSMC to review and confirm the responses on the AIR.

A limited regulatory review (i.e., reviewing protocol and consent versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by the DSMC for regulatory compliance.

Monitoring of all enrolled participants in these trials will be complete after all enrolled participants have been monitored through first cycle of treatment. However, regulatory reviews of the trial, safety reviews (i.e., Serious Adverse Event (SAE) reviews and Protocol Violation (PV) reviews), and audit/inspection preparation (as applicable) will continue until the trial is closed by the IRB.

The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites to communicate the review of adverse events, safety data, and other study matters.

**Multicenter communication**

The UCSF Coordinating Center includes the UCSF PI (Study Chair) and the UCSF study team. The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites. The following issues will be discussed as appropriate:

* Enrollment information.
* Adverse events
* Protocol Violations.
* Other issues affecting the conduct of the study.

Adverse events reporting to the DSMC will include reports from both the UCSF Coordinating Center, as well as the participating sites. The DSMC will be responsible for monitoring all data entered in OnCore at the UCSF Coordinating Center and the participating sites as per the study-specific guidelines. The data (i.e., redacted copies of source documents) from the participating sites will be downloaded into the CRA module of OnCore prior to the monitoring visits in order for the monitoring of the participating site’s compliance with the protocol and applicable FDA regulations.

1. **Review and Oversight Requirement**
   1. **Adverse Event Monitoring**

All clinically significant adverse events (AEs), whether or not considered to be expected or unexpected and whether or not considered to be associated with the use of study drug, will be entered into OnCore, UCSF’s Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to investigational agent or study procedure. Attribution categories are:

* + - **Definite** – clearly related to the investigational agent(s) or study procedure.
    - **Probable** – likely related to the investigational agent(s) or study procedure.
    - **Possible** – may be related to the investigational agent(s) or study procedure.
    - **Unrelated** – clearly not related to the investigational agent(s) or study procedure.

All adverse events entered into OnCore® will be reviewed on a weekly basis at the UCSF Coordinating Center’s Site Committee meetings. The UCSF Site Committee will review and discuss the selected toxicity, grade, and the attribution assignment for the adverse events that occurred at both the UCSF Coordinating Center and the participating sites.

* 1. **Serious Adverse Event Reporting**

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

* + - Death,
    - Life-threatening adverse experience\*,
    - Inpatient hospitalization or prolongation of existing hospitalization,
    - Persistent or significant disability/incapacity,
    - Congenital anomaly/birth defect, or cancer, or
    - Any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above,
    - Event that changes the risk/benefit ratio of the study.

\* A life-threatening adverse experience is any AE that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event reporting will be in accordance with all IRB regulations. For trials conducted under an investigational new drug (IND) application, the SAE will be reported in accordance with Code of Federal Regulation Title 21 Part 312.32 and will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events: <https://irb.ucsf.edu/adverse-event>

Med Watch forms and information: [www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm)

All serious adverse events are entered into OnCore. All SAEs, whether expected or unexpected, must be reported to the UCSF Coordinating Center within one business days of becoming aware of the event.

The SAEs are reviewed and monitored by the Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every eight weeks. The date the SAE report was sent to all required reporting agencies will be documented in OnCore.

If a death occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s) and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Study Chair at the UCSF Coordinating Center or the assigned designee must be notified within one business day from the participating site(s) and the Study Chair must then

notify the DSMC Chair or Vice Chair and DSMC Director within one business day of this notification.

* 1. **Review of Adverse Event Rates**

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Study Chair at

the UCSF Coordinating Center is responsible for notifying the DSMC at the time the increased rate is identified. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the Study Chair holds enrollment or stops the study due to safety issues, the DSMC Chair or Vice Chair and DSMC Director must be notified within one business day via e-mail and the IRB must be notified within their reporting requirements.

* 1. **Data and Safety Monitoring Board (DSMB) Reports**

Data and Safety Monitoring Board (DSMB) Reports which provide information on trial accrual, participant safety, and data integrity will be provided to all sites, including the domestic and international sites, on an annual basis. The DSMB Report will be signed by the DSMC Chair (or Vice Chair) and provided to the DSMC Committee for formal review at the next scheduled DSMC Committee meeting.

**Data and Safety Monitoring Committee Contacts:**

|  |
| --- |
| Katie Kelley, MD (DSMC Chair) |
| 415-353-9888  [Katie.kelley@ucsf.edu](mailto:Katie.kelley@ucsf.edu) Box 3211  UCSF HDFCCC  San Francisco, CA 94158 |
| John McAdams (DSMC Director) 415-476-8496  [John.mcadams@ucsf.edu](mailto:John.mcadams@ucsf.edu) Box 0981  UCSF HDFCCC  San Francisco, CA 94158 |

**Appendix N.10 (Multicenter) Phase II, III, or IV Trial**

**Data and Safety Monitoring Plan for a Multicenter Study Phase II, III, or IV Trial**

1. **Oversight and Monitoring Plan**

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for auditing data quality and participant safety for all HDFCCC institutional clinical trials. A summary of DSMC activities for this trial includes:

* + Annual auditing (depending on accrual).
  + Review of serious adverse events.
  + Minimum of a biennial regulatory auditing visit.

1. **Monitoring and Reporting Guidelines**

The Principal Investigator at the UCSF Coordinating Center will hold the role of Study Chair. The Study Chair is responsible for the overall conduct of the trial and for auditing its safety and progress at all participating sites. The Study Chair will conduct continuous review of data and participant safety at monthly UCSF Site Committee meetings. The discussions are documented in the UCSF Site Committee meeting minutes.

The UCSF HDFCCC Data and Safety Monitoring Committee (DSMC) is responsible for participant safety for all domestic sites for HDFCCC Multicenter and Consortium institutional clinical trials. The International sites must be audited by a Clinical Research Organization (CRO) that is formally approved by the HDFCCC Cancer Center Clinical Research Oncology Committee (CCCROC) and the HDFCCC DSMC via the [HDFCCC](https://cancer.ucsf.edu/itr/sm_files/Policy_on_Minimum_Standards_for_Partnerships_with_International_CROs_current.pdf) [Policy of Minimum Standards for Partnership with International CROs.](https://cancer.ucsf.edu/itr/sm_files/Policy_on_Minimum_Standards_for_Partnerships_with_International_CROs_current.pdf)

All institutional Phase II, III, or IV therapeutic trials are generally designated with a moderate risk assessment. The DSMC DSA will audit up to a maximum of three cycles of treatment for each participant selected for the annual audit. The assigned DSA will review 20% of the total number of participants enrolled in the trial at UCSF and at least 1 participant at each participating site. A total of 1 participant per site will be required to be reviewed, unless there are participants enrolled in cohorts that require all participants to be reviewed (i.e., study lead-in or rolling 6 cohorts).

The DSA will send both a Monitoring Visit Report (MVR) and an Action Item Report (AIR) to the study team within 1 calendar month after the monitoring visit is complete to be completed within 8 weeks. The due date for the completion of the action items may be extended for up to an additional 2 months for extenuating circumstances, if approved by the DSMC. The AIR report must be completed by the study team prior to the next review of this study.

Additionally, the action items from the AIR Report must be deemed answered and complete by the DSA after the report has been submitted by the study team; hence, the completed AIR must be sent to the DSMC by 4 weeks prior to the deadline for the DSA’s review and confirmation of these completed action items. If the study team is granted a second extension by the DSMC Director, then the DSA will have 4 weeks after the report has been provided to the DSMC to review and confirm the responses on the AIR.

A limited regulatory review (i.e., reviewing protocol and consent versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by the DSMC for regulatory compliance.

Auditing of all enrolled participants in these trials will be complete after a total of 20% of enrolled participants have been audited through three cycles of treatment. However, regulatory reviews of the trial, safety reviews (i.e., Serious Adverse Event (SAE) reviews and Protocol Violation (PV) reviews), and audit/inspection preparation (as applicable) will continue until study closure.

The participating site’s source documents are audited remotely via review of redacted source documents downloaded by the site into the CRA console of OnCore. The DSA will audit up to three participant charts at each participating site during the course of auditing this trial.

**Multicenter communication**

The UCSF Coordinating Center includes the UCSF PI (Study Chair) and the UCSF study team. The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites. The following issues will be discussed as appropriate:

* Enrollment information.
* Adverse events.
* Protocol Violations.
* Other issues affecting the conduct of the study.

Adverse events reporting to the DSMC will include reports from both the UCSF Coordinating Center, as well as the participating sites. The data (i.e., copies of source documents) from the participating sites will be downloaded into the PC console of OnCore prior to the remote monitoring visits in order for the DSMC to monitor the participating site’s compliance with the protocol and applicable FDA regulations.

1. **Review and Oversight Requirements**
   1. Adverse Event Monitoring

All Grade 3-5 adverse events (AEs), regardless of being unexpected or considered to be associated with the use of the study drug will be entered into OnCore, UCSF’s Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to the investigational agent(s) or study procedure. Attribution categories are:

* + - **Definite** – clearly related to the investigational agent(s) or study procedure.
    - **Probable** – likely related to the investigational agent(s) or study procedure.
    - **Possible** – may be related to the investigational agent(s) or study procedure.
    - **Unrelated** – clearly not related to the investigational agent(s) or study procedure.

All Grade 3-5 adverse events entered into OnCore will be reviewed on a monthly basis at the UCSF Site Committee meetings. All adverse events entered into OnCore® will be reviewed on a monthly basis at the UCSF Coordinating Center Site Committee meetings. All grade 3-5 adverse events must be reported to the UCSF Coordinating Center by the participating sites within 10 business days of becoming aware of the event or during the next scheduled monthly conference call, whichever is sooner. The UCSF

Site Committee will review and discuss the selected toxicity, the toxicity grade, and attribution assignment from the UCSF Coordinating Center and the participating sites.

* 1. **Serious Adverse Event Reporting**

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

* + - Death,
    - Life-threatening adverse experience\*,
    - Inpatient hospitalization or prolongation of existing hospitalization,
    - Persistent or significant disability/incapacity,
    - Congenital anomaly/birth defect, or cancer, or
    - Any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above,
    - Event that changes the risk/benefit ratio of the study.

\* A life-threatening adverse experience is any AE that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event reporting will be in accordance with all IRB regulations. For trials conducted under an investigational new drug (IND) application, the SAE will be reported in accordance with Code of Federal Regulation Title 21 Part 312.32 and will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events: <https://irb.ucsf.edu/adverse-event>

Med Watch forms and information: [www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm)

All serious adverse events are entered into OnCore. All SAEs, whether expected or unexpected, must be reported to the UCSF Coordinating Center within one business days of becoming aware of the event. The SAEs are reviewed and audited by the UCSF Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every eight weeks. The date the SAE report was sent to all required reporting agencies will be documented in OnCore.

If a death occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s) and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, the Study Chair at the UCSF Coordinating Center or the assigned designee must be notified within 1 business day from the participating site(s) and the Study Chair must then notify the DSMC Chair or Vice Chair and the DSMC Director within 1 business day of this notification.

* 1. **Review of Adverse Event Rates**

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Study Chair at

the UCSF Coordinating Center is responsible for notifying the DSMC Chair (or Vice Chair) and the DSMC Director at the time the increased rate is identified via a report. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator Brochure or package insert.

If at any time the Study Chair stops enrollment or stops the study due to safety issues, the DSMC Chair (or Vice Chair) and the DSMC Director must be notified within one business day and the IRB must be notified within their reporting guidelines.

* 1. **Data and Safety Monitoring Board (DSMB) Reports**

Data and Safety Monitoring Board (DSMB) Reports which provide information on trial accrual, participant safety, and data integrity will be provided to all sites, including the domestic and international sites, on an annual basis. The DSMB Report will be signed by the DSMC Chair (or Vice Chair) and provided to the DSMC Committee for formal review at the next scheduled DSMC Committee meeting.

**Data and Safety Monitoring Committee Contacts:**

|  |
| --- |
| Katie Kelley, MD (DSMC Chair) |
| 415-353-9888  [Katie.kelley@ucsf.edu](mailto:Katie.kelley@ucsf.edu) Box 3211  UCSF HDFCCC  San Francisco, CA 94158 |
| John McAdams (DSMC Director) 415-476-8496  [John.mcadams@ucsf.edu](mailto:John.mcadams@ucsf.edu) Box 0981  UCSF HDFCCC  San Francisco, CA 94158 |

**Appendix N.11 (Multicenter) Phase II, III, or IV Trial with Safety Lead-In Phase**

**Data and Safety Monitoring Plan: Multicenter Phase II, III, or IV Trial with Safety Lead-In**

1. **Oversight and Monitoring Plan**

The UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) Data and Safety Monitoring Committee (DSMC) is responsible for auditing data quality and participant safety for all HDFCCC institutional clinical trials. A summary of DSMC activities for this trial includes:

* + Review of all participant data in safety lead-in phase.
  + Approval to enroll past safety lead-in phase by DSMC Chair or Vice Chair.
  + Annual auditing after safety lead-in phase (depending on accrual).
  + Review of serious adverse events.
  + Minimum of a biennial regulatory auditing visit.

1. **Monitoring and Reporting Guidelines**

The Principal Investigator at the UCSF Coordinating Center will hold the role of Study Chair. The Study Chair is responsible for the overall conduct of the trial and for auditing its safety and progress at all participating sites. The Study Chair will conduct continuous review of data and participant safety at monthly UCSF Site Committee meetings. The discussions are documented in the UCSF Site Committee meeting minutes.

The UCSF HDFCCC Data and Safety Monitoring Committee (DSMC) is responsible for participant safety for all domestic sites for HDFCCC Multicenter and Consortium institutional clinical trials. The International sites must be audited by a Clinical Research Organization (CRO) that is formally approved by the HDFCCC Cancer Center Clinical Research Oncology Committee (CCCROC) and the HDFCCC DSMC via the [HDFCCC](https://cancer.ucsf.edu/itr/sm_files/Policy_on_Minimum_Standards_for_Partnerships_with_International_CROs_current.pdf) [Policy of Minimum Standards for Partnership with International CROs.](https://cancer.ucsf.edu/itr/sm_files/Policy_on_Minimum_Standards_for_Partnerships_with_International_CROs_current.pdf)

All institutional Phase II, III, or IV therapeutic studies with a lead-in are generally designated with a high-risk assessment during the safety lead-in phase and a moderate risk assessment. During the safety lead-in phase, the DSMC will audit all visits through the first cycle of treatment for all participants enrolled in this phase of the trial.

After the completion of enrollment in the safety lead-in phase, the Study Chair will submit a report to the DSMC Chair outlining all AEs, SAEs, and DLTs (as defined in the protocol) with a request to proceed onto the next phase of the trial. Within two business days of receipt, the DSMC Chair or designee will review the report and issue written authorization to proceed or a request for more information. The report is then reviewed at the subsequent DSMC meeting. However, if there are AIRs that are past the due date for completions (i.e., post 8 week timeline or post 12-16 week timeline if extensions were granted), then the safety lead-in review will be postponed until these action items are all addressed by the study team.

After DSMC authorization to enroll beyond the safety lead-in phase is granted, study data is audited by a DSMC Data and Safety Auditor on an annual basis with a random selection of 20% of the total number of participants (no more than 10 participants). The DSMC Data and Safety Auditor will audit a maximum of three cycles of treatment in the participants selected for review until study closure. The DSA will send both a Monitoring Visit Report (MVR) and an Action Item Report (AIR) to the study team within 1 calendar month after completion of the monitoring visit to be completed within 8 weeks. The due date for the completion

of the action items may be extended for up to an additional 2 months for extenuating circumstances, if approved by the DSMC. The AIR report must be completed by the study team prior to the next review of this study. A limited regulatory review (i.e., reviewing protocol and consent versions, SAEs, PVs, DOA logs, 1572 forms, etc.) will occur at each participant monitoring review; however, a full regulatory review will occur on a biennially basis by the DSMC for regulatory compliance.

The participating site’s source documents are audited remotely via either review of redacted source documents downloaded by the site into the CRA console of OnCore. The DSMC Monitor/Auditor will audit no more than three participant charts at each participating site during the course of auditing this trial.

Auditing of all enrolled participants in these trials will be complete after 20% of enrolled participants enrolled at UCSF and at least one participant chart from each participating site have been reviewed. However, regulatory reviews of the trial, safety reviews (i.e., Serious Adverse Event (SAE) reviews and Protocol Violation (PV) reviews), and audit/inspection preparation (as applicable) will continue until study closure.

**Multicenter communication**

The UCSF Coordinating Center includes the UCSF PI (Study Chair) and the UCSF study team. The UCSF Coordinating Center provides administration, data management, and organizational support for the participating sites in the conduct of a multicenter clinical trial. The UCSF Coordinating Center will also coordinate monthly conference calls with the participating sites. The following issues will be discussed as appropriate:

* Enrollment information.
* Adverse events (i.e., new adverse events and updates on unresolved adverse events and new safety information).
* Protocol Violations.
* Other issues affecting the conduct of the study.

Adverse events reporting to the DSMC will include reports from both the UCSF Coordinating Center, as well as the participating sites. The data (i.e., copies of source documents) from the participating sites will be downloaded into the PC console of OnCore prior to the remote monitoring visits in order for the DSMC to monitor the participating site’s compliance with the protocol and applicable FDA regulations.

1. **Review and Oversight Requirements**
   1. **Adverse Event Monitoring**

All Grade 3-5 adverse events (AEs), whether or not considered to be expected or unexpected and whether or not considered to be associated with the investigational agent(s) or study procedure, will be entered into OnCore, UCSF’s Clinical Trial Management System.

Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) as developed and revised by the Common Therapy Evaluation Program (CTEP) of the National Cancer Institute. Adverse events are further given an assignment of attribution or relationship to the investigational agent(s) or study procedure. Attribution categories are:

* + - **Definite** – clearly related to the investigational agent(s) or study procedure.
    - **Probable** – likely related to the investigational agent(s) or study procedure.
    - **Possible** – may be related to the investigational agent(s) or study procedure.
    - **Unrelated** – clearly not related to the investigational agent(s) or study procedure.

All Grade 3-5 adverse events entered into OnCore will be reviewed on a monthly basis at the UCSF Site Committee meetings. All adverse events entered into OnCore will be reviewed on a monthly basis at the UCSF Coordinating Center Site Committee meetings. All grade 3-5 adverse events must be reported to the UCSF Coordinating Center by the participating sites within 10 business days of becoming aware of the event or during the next scheduled monthly conference call, whichever is sooner. The UCSF Site Committee will review and discuss the selected toxicity, the toxicity grade, and the attribution assignment from the UCSF Coordinating Center and the participating sites.

* 1. **Serious Adverse Event Reporting**

By definition, an adverse event is defined as a serious adverse event (SAE) according to the following criteria:

* + - Death,
    - Life-threatening adverse experience\*,
    - Inpatient hospitalization or prolongation of existing hospitalization,
    - Persistent or significant disability/incapacity,
    - Congenital anomaly/birth defect, or cancer, or
    - Any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above,
    - Event that changes the risk/benefit ratio of the study.

\* A life-threatening adverse experience is any AE that places the patient or subject, in the view of the investigator, at immediate risk of death from the reaction as it occurred, i.e., it does not include a reaction that, had it occurred in a more severe form, might have caused death.

Serious adverse event reporting will be in accordance with all IRB regulations. For trials conducted under an investigational new drug (IND) application, the SAE will be reported in accordance with Code of Federal Regulation Title 21 Part 312.32 and will be reported on a Med Watch form.

UCSF IRB website for guidance in reporting serious adverse events: <https://irb.ucsf.edu/adverse-event>

Med Watch forms and information: [www.fda.gov/medwatch/getforms.htm](http://www.fda.gov/medwatch/getforms.htm)

All serious adverse events are entered into OnCore. All SAEs, whether expected or unexpected, must be reported to the UCSF Coordinating Center within one business days of becoming aware of the event. The SAEs are reviewed and audited by the UCSF Data and Safety Monitoring Committee on an ongoing basis and discussed at DSMC meetings, which take place every eight weeks. The date the SAE report was sent to all

required reporting agencies will be documented in OnCore.

If a death occurs during the treatment phase of the study or within 30 days after the last administration of the study drug(s) and is determined to be possibly, probably, or definitely related either to the investigational drug or any research related procedure, then the Study Chair at the UCSF Coordinating Center or the assigned designee must be notified within 1 business day from the participating site(s) and the Study Chair must then notify the DSMC Chair (or Vice Chair) and the DSMC Director within 1 business day of this notification.

* 1. **Review of Adverse Event Rates**

If an increase in the frequency of Grade 3 or 4 adverse events (above the rate reported in the Investigator Brochure or package insert) is noted in the study, the Study Chair at the UCSF Coordinating Center is responsible for notifying the DSMC Chair (or Vice Chair) and the DSMC Director at the time the increased rate is identified via a report. The report will indicate if the incidence of adverse events observed in the study is above the range stated in the Investigator’s Brochure or package insert.

If at any time the Study Chair stops enrollment or stops the study due to safety issues, the DSMC Chair (or Vice Chair) and the DSMC Director must be notified within one business day and the IRB must be notified within their reporting guidelines.

* 1. **Data and Safety Monitoring Board (DSMB) Reports**

Data and Safety Monitoring Board (DSMB) Reports which provide information on trial accrual, participant safety, and data integrity will be provided to all sites, including the domestic and international sites, on an annual basis. The DSMB Report will be signed by the DSMC Chair (or Vice Chair) and provided to the DSMC Committee for formal review at the next scheduled DSMC Committee meeting.

**Data and Safety Monitoring Committee Contacts:**

|  |
| --- |
| Katie Kelley, MD (DSMC Chair) |
| 415-353-9888  [Katie.kelley@ucsf.edu](mailto:Katie.kelley@ucsf.edu) Box 3211  UCSF HDFCCC  San Francisco, CA 94158  John McAdams (DSMC Director) 415-476-8496  [John.mcadams@ucsf.edu](mailto:John.mcadams@ucsf.edu) Box 0981  UCSF HDFCCC  San Francisco, CA 94158 |

**Appendix O. Risk Assessment for Institutional Studies**

The table below lists the risk assessment for the institutional studies monitored by the DSMC.

|  |  |  |  |
| --- | --- | --- | --- |
| **Risk assignment** | **Study type** | **Monitoring** | **Surveillance** |
| **High** | Institutional Phase 1 dose-escalation therapeutic | Monitor all participants in real-time as prior to dose escalation through DLT period. Once DLT is determined, then audit 20% of participants (up to a maximum of 3/year or a total of 10 participants) through first three cycles of therapy, all study staff are required to receive HDFCCC training prior to working on trial. | Real time monitoring of AEs and SAEs weekly at site committees; DSMC monitors SAEs every eight weeks at DSMC Meetings |
| **High** | Non-dose finding Phase I Institutional therapeutic | Monitor all participants on a quarterly basis as enrolled through the first cycle of therapy, all study staff are required to receive HDFCCC training prior to working on trial. | Real time monitoring of AEs and SAEs weekly at site committees; DSMC monitors SAEs every eight weeks at DSMC Meetings |
| **Moderate** | Institutional Phase II therapeutic | Audit first three cycles of treatment in 20% of study participants (up to a maximum of 10 participants or 3 per year) on an annual basis, all study staff are required to receive HDFCCC  training prior to working on trial. | Real time monitoring of AEs and SAEs monthly at site committees; DSMC monitors SAEs every eight weeks at DSMC Meetings |
| **Moderate** | Institutional Phase II therapeutic with Safety Lead-In | Monitor all patients in the safety lead-in cohort, then audit first three cycles of treatment in 20% of study participants (up to a maximum of 3 per year or a total of 10 participants) thereafter on an annual basis, all study staff are required to receive HDFCCC training prior to working on trial. | Real time monitoring of AEs and SAEs monthly at site committees; DSMC monitors SAEs every eight weeks at DSMC Meetings |

|  |  |  |  |
| --- | --- | --- | --- |
| **Moderate** | Institutional Phase III therapeutic | Audit first three cycles of treatment in 20% of participants (up to a maximum of 3 per year or a total of 10 participants) on an annual basis., All study staff are required to receive  HDFCCC training prior to working on trial. | Real time monitoring of AEs and SAEs monthly at site committees; DSMC monitors for SAEs every eight weeks at DSMC Meetings |
| **Moderate** | Institutional Phase IV/other therapeutic | Audit a pre-determined number of cycles of treatment | Real time monitoring of AEs and SAEs monthly at |

|  |  |  |  |
| --- | --- | --- | --- |
| **Risk assignment** | **Study type** | **Monitoring** | **Surveillance** |
|  |  | and/or specific time period post-intervention (according to the window of risk for the intervention being studied as pre-defined in protocol) in 20% of participants on an annual basis. All study staff are required to receive HDFCCC training prior to working on trial. | site committees; DSMC monitors for SAEs every eight weeks at DSMC Meetings |
| **Low** | Non-therapeutic trials with research specific study procedures that are deemed above minimal risk (i.e., novel tracers for radiology trials) | Audit participants enrolled in trial once per year, with a total of 20% of participants reviewed, up to a maximum of ten total participants overall reviewed. All study staff are required to receive HDFCCC training prior to working on trial. | Real time monitoring of AEs and SAEs monthly at site committees; DSMC monitors for SAEs every eight weeks at DSMC Meetings |
| **Minimal Risk** | Non-therapeutic trials with minimal risk study procedures | Not responsible for auditing, all study staff are required to receive HDFCCC training prior to working on trial. | Real time monitoring of SAEs monthly at site committees; DSMC monitors for SAEs every eight weeks at DSMC Meetings |